BioCentury | Aug 15, 2016
Clinical News

DAd5GNE: Phase I started

...placebo-controlled, U.S. Phase I trial to evaluate 6 injections of 100, 316 and 1,000 ug dAd5GNE...
...Abuse (NIDA) are funding the trial. Weill Cornell Medical College , New York, N.Y. Product: DAd5GNE...
BioCentury | Nov 12, 2012
Clinical News

Immunovaccine preclinical data

...In mice, dAd5GNE DepoVax vaccine produced high levels of target antibodies that were able to sequester...
...antibodies that were able to sequester cocaine in blood and block delivery to the brain. dAd5GNE...
...generate an immune response (see BioCentury, March 19). Immunovaccine Inc. (TSX-V:IMV), Halifax, Nova Scotia Product: DAd5GNE...
Items per page:
1 - 2 of 2